Geneva, Oct. 8 -- International Clinical Trials Registry received information related to the study (ACTRN12625001062415) titled 'ALLG LS26: Minimal Residual Disease and the Immune Microenvironment in Amyloidosis' on Sept. 26.
Study Type: Observational
Primary Sponsor: Australasian Leukaemia and Lymphoma Group
Condition:
Amyloidosis
Amyloidosis
Cancer - Other cancer types
Inflammatory and Immune System - Other inflammatory or immune system disorders
Metabolic and Endocrine - Other metabolic disorders
Intervention:
Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (D-VCD) is the standard of care (SOC) for front-line treatment of amyloid light chain (AL) Amyloidosis patients. The treatment regime of D-VCD is 6 cycles with ea...